JP2019517505A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517505A5 JP2019517505A5 JP2018563009A JP2018563009A JP2019517505A5 JP 2019517505 A5 JP2019517505 A5 JP 2019517505A5 JP 2018563009 A JP2018563009 A JP 2018563009A JP 2018563009 A JP2018563009 A JP 2018563009A JP 2019517505 A5 JP2019517505 A5 JP 2019517505A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- administered
- months
- dose
- lymphoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022130733A JP2022176973A (ja) | 2016-06-02 | 2022-08-18 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
| JP2023176091A JP2024020202A (ja) | 2016-06-02 | 2023-10-11 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662344866P | 2016-06-02 | 2016-06-02 | |
| US62/344,866 | 2016-06-02 | ||
| US201662382839P | 2016-09-02 | 2016-09-02 | |
| US62/382,839 | 2016-09-02 | ||
| PCT/US2017/035521 WO2017210473A1 (en) | 2016-06-02 | 2017-06-01 | Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022130733A Division JP2022176973A (ja) | 2016-06-02 | 2022-08-18 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019517505A JP2019517505A (ja) | 2019-06-24 |
| JP2019517505A5 true JP2019517505A5 (enExample) | 2020-07-16 |
| JP7641704B2 JP7641704B2 (ja) | 2025-03-07 |
Family
ID=59067913
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563009A Active JP7641704B2 (ja) | 2016-06-02 | 2017-06-01 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
| JP2022130733A Pending JP2022176973A (ja) | 2016-06-02 | 2022-08-18 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
| JP2023176091A Pending JP2024020202A (ja) | 2016-06-02 | 2023-10-11 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022130733A Pending JP2022176973A (ja) | 2016-06-02 | 2022-08-18 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
| JP2023176091A Pending JP2024020202A (ja) | 2016-06-02 | 2023-10-11 | リンパ腫処置における抗ｃｄ３０抗体と組み合わせた抗ｐｄ－１抗体の使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11299543B2 (enExample) |
| EP (2) | EP3464368B1 (enExample) |
| JP (3) | JP7641704B2 (enExample) |
| KR (3) | KR20240145059A (enExample) |
| CN (1) | CN109476752A (enExample) |
| AU (2) | AU2017274444B2 (enExample) |
| BR (1) | BR112018074619A2 (enExample) |
| CA (1) | CA3026246A1 (enExample) |
| DK (1) | DK3464368T3 (enExample) |
| ES (1) | ES2951650T3 (enExample) |
| FI (1) | FI3464368T3 (enExample) |
| HU (1) | HUE063911T2 (enExample) |
| IL (1) | IL263165A (enExample) |
| MX (2) | MX390955B (enExample) |
| PL (1) | PL3464368T3 (enExample) |
| PT (1) | PT3464368T (enExample) |
| SG (2) | SG10202101062YA (enExample) |
| SI (1) | SI3464368T1 (enExample) |
| WO (1) | WO2017210473A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| MX390955B (es) | 2016-06-02 | 2025-03-19 | Seagen Inc | Uso de un anticuerpo anti-pd-1 en combinación con un anticuerpo anti-cd30 para el tratamiento de linfoma. |
| MA50369A (fr) * | 2017-10-13 | 2020-08-19 | Seattle Genetics Inc | Modulation de la réponse immunitaire à l'aide de conjugués anticorps-médicament |
| WO2019140150A1 (en) * | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer |
| JP7460608B2 (ja) * | 2018-05-07 | 2024-04-02 | ジェンマブ エー／エス | 抗ｐｄ－１抗体と抗組織因子抗体－薬物コンジュゲートとの組み合わせを用いるがんの治療方法 |
| TWI920652B (zh) | 2018-06-07 | 2026-04-01 | 美商思進公司 | 喜樹鹼結合物 |
| TWI844571B (zh) | 2018-10-30 | 2024-06-11 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法 |
| US20220144960A1 (en) | 2018-12-26 | 2022-05-12 | Nanjing Legend Biotech Co., Ltd. | Cd30-binding moieties, chimeric antigen receptors, and uses thereof |
| KR20220069964A (ko) | 2019-09-25 | 2022-05-27 | 씨젠 인크. | 조혈암의 치료를 위한 항-cd30 adc, 항-pd-1 및 화학치료제 조합 |
| MX2022006891A (es) | 2019-12-09 | 2022-09-09 | Seagen Inc | Terapia combinada con liv1-adc y antagonista de pd-1. |
| CN111407894B (zh) * | 2020-02-21 | 2022-04-29 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种治疗复发/难治t细胞淋巴瘤的新型联合靶向药物 |
| KR20230023650A (ko) * | 2020-05-13 | 2023-02-17 | 씨젠 인크. | 항-cd30 항체-약물 컨쥬게이트의 조합을 사용하여 암을 치료하는 방법 |
| CN116964098A (zh) | 2021-03-01 | 2023-10-27 | 南特生物公司 | 抗cd30单克隆抗体和嵌合抗原受体 |
| CN118987233A (zh) * | 2024-08-08 | 2024-11-22 | 武汉科技大学 | 治疗经典型霍奇金淋巴瘤的药物组合物及其用途 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2539411T3 (es) | 1999-08-23 | 2015-06-30 | Dana-Farber Cancer Institute, Inc. | PD-1, receptor para la B7-4 y su utilización |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| CN101490085A (zh) * | 2006-06-12 | 2009-07-22 | 特鲁比昂药品公司 | 具有效应功能的单链多价结合蛋白 |
| CL2007003622A1 (es) * | 2006-12-13 | 2009-08-07 | Medarex Inc | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| US8877202B2 (en) * | 2013-02-07 | 2014-11-04 | Immunomedics, Inc. | Pro-drug form (P2PDOX) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer |
| DK3896088T3 (da) * | 2013-02-20 | 2025-09-29 | Innate Pharma | Behandling af perifert t-cellelymfom |
| RS61400B1 (sr) | 2013-05-02 | 2021-02-26 | Anaptysbio Inc | Antitela usmerena protiv programirane smrti-1 (pd-1) |
| CA3175360C (en) | 2013-05-31 | 2024-05-28 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| EP3066127A1 (en) * | 2013-11-06 | 2016-09-14 | Bristol-Myers Squibb Company | Immunotherapeutic dosing regimens and combinations thereof |
| US20160303231A1 (en) * | 2013-12-11 | 2016-10-20 | Robert Iannone | Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor |
| CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| MX390955B (es) | 2016-06-02 | 2025-03-19 | Seagen Inc | Uso de un anticuerpo anti-pd-1 en combinación con un anticuerpo anti-cd30 para el tratamiento de linfoma. |
| HUE062398T2 (hu) | 2016-06-02 | 2023-10-28 | Bristol Myers Squibb Co | PD-1 blokád nivolumabbal refrakter Hodgkin limfómában |
-
2017
- 2017-06-01 MX MX2018014610A patent/MX390955B/es unknown
- 2017-06-01 CA CA3026246A patent/CA3026246A1/en active Pending
- 2017-06-01 ES ES17730629T patent/ES2951650T3/es active Active
- 2017-06-01 KR KR1020247031531A patent/KR20240145059A/ko not_active Ceased
- 2017-06-01 WO PCT/US2017/035521 patent/WO2017210473A1/en not_active Ceased
- 2017-06-01 KR KR1020187037834A patent/KR102710067B1/ko active Active
- 2017-06-01 JP JP2018563009A patent/JP7641704B2/ja active Active
- 2017-06-01 KR KR1020237026623A patent/KR20230119265A/ko not_active Ceased
- 2017-06-01 SG SG10202101062YA patent/SG10202101062YA/en unknown
- 2017-06-01 FI FIEP17730629.7T patent/FI3464368T3/fi active
- 2017-06-01 BR BR112018074619A patent/BR112018074619A2/pt not_active Application Discontinuation
- 2017-06-01 US US16/306,282 patent/US11299543B2/en active Active
- 2017-06-01 SI SI201731383T patent/SI3464368T1/sl unknown
- 2017-06-01 PT PT177306297T patent/PT3464368T/pt unknown
- 2017-06-01 HU HUE17730629A patent/HUE063911T2/hu unknown
- 2017-06-01 EP EP17730629.7A patent/EP3464368B1/en active Active
- 2017-06-01 AU AU2017274444A patent/AU2017274444B2/en active Active
- 2017-06-01 SG SG11201810454YA patent/SG11201810454YA/en unknown
- 2017-06-01 DK DK17730629.7T patent/DK3464368T3/da active
- 2017-06-01 CN CN201780048015.7A patent/CN109476752A/zh active Pending
- 2017-06-01 EP EP23174305.5A patent/EP4248989A3/en not_active Withdrawn
- 2017-06-01 PL PL17730629.7T patent/PL3464368T3/pl unknown
-
2018
- 2018-11-21 IL IL263165A patent/IL263165A/en unknown
- 2018-11-27 MX MX2022003571A patent/MX2022003571A/es unknown
-
2022
- 2022-04-07 US US17/715,875 patent/US20220298243A1/en not_active Abandoned
- 2022-08-18 JP JP2022130733A patent/JP2022176973A/ja active Pending
-
2023
- 2023-10-11 JP JP2023176091A patent/JP2024020202A/ja active Pending
-
2024
- 2024-10-30 AU AU2024227762A patent/AU2024227762A1/en active Pending